Jyseleca® approved in UC in Great Britain

Jyseleca® approved in UC in Japan

Appointment of Dr. Paul Stoffels as CEO and Chairman

Expansion into oncology with acquisitions of CellPoint (NL) and AboundBio (US)

Positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies

New R&D strategy and fit-for-purpose organization

Initial encouraging results from FILOSOPHY real-world study of filgotinib in RA

CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors

Initial encouraging Phase 1/2 results for CD19 CAR-T in rrNHL manufactured at point-of-care

Set-up of new Management Committee and announced changes to the Executive Committee